Exact Sciences received FDA approval for Cologuard Plus, an improved stool-based screening test for colon cancer. The new test is designed to reduce unnecessary follow-up colonoscopies for cancer-free patients. Cologuard Plus was approved for adults aged 45 and older with an average cancer risk, based on positive results from the Blue-C clinical trial with over 20,000 participants. The test was found to detect 94% of cancers and 43% of advanced precancers, with a specificity rate of 91% for correctly identifying participants without colon cancer or advanced precancer.
Source link
Exact Sciences gets FDA nod for improved colon cancer test
